Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Immunocore Holdings plc

Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports third quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to present at the 2024 Cantor Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore announces transition of Chief Financial Officer
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore to present at the Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Immunocore announces upcoming presentation and posters at ASCO 2024
From Immunocore Holdings plc
Via GlobeNewswire
Tickers IMCR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.